AstraZeneca rose about 2% before the market opened. Chronic lymphocytic leukemia treatment achieved good results

Market Information 29/07/2024 16:55

AstraZeneca (AZN.US) US stocks rose 1.7% to $79.46 in pre-market trading. In the news, the company said that the results of its Calquence drug for the treatment of chronic lymphocytic leukemia were favorable. The company said that Calquence showed statistically significant and clinically important improvements in progression-free survival in untreated adult patients in the Amplify Phase III trial in combination with venetoclax, with or without obinutuzumab.

.

Disclaimer: The content is provided as general information only and should not be taken as investment advice. All the contents shall not be taken as a recommendation to buy or sell any security or financial instruments. Any action you take resulting from information, analysis, or commentary on this article is your responsibility. Please consult your investment advisor before making any investments.